- Scrip
- >>Business
- >>Financing
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Kriya, Adlai Nortye Also Closed VC Mega-Rounds
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
Amylyx Pharmaceuticals, Inc. announced Phase II/III results for AMX0035 in the treatment of amyotrophic lateral sclerosis (ALS) last year and hoped to obtain US Food and Drug Administration approval as soon as possible. Now the company has raised $135m in series C venture capital to fund regulatory submissions and conduct a Phase III clinical trial, but the timing of a US filing remains yet to be determined.
[Sidebar#SC142912]